Chronic Plaque Psoriasis Market
Report ID: SQMIG35I3379
Report ID: SQMIG35I3379
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35I3379 |
Region:
Global |
Published Date: July, 2026
Pages:
157
|Tables:
179
|Figures:
79
Global Chronic Plaque Psoriasis Market size was valued at USD 29.5 Billion in 2024 and is poised to grow from USD 31.51 Billion in 2025 to USD 53.42 Billion by 2033, growing at a CAGR of 6.82% during the forecast period (2026-2033).
The global chronic plaque psoriasis market trends includes therapies, diagnostics, and patient support services for the management of the most common type of psoriasis. The importance of this disease is related to its impact on quality of life, healthcare costs and the growing prevalence of autoimmune diseases worldwide. Topical corticosteroids dominated the market, however the advent of biologics such as ustekinumab and secukinumab in the early 2010s heralded a move towards targeted immune modulation. The arrival of biosimilar competitors in 2015 increased access in emerging economies and reduced pricing barriers, accelerating this transition and driving steady revenue growth.
Investors are now closely watching the progress of the pipeline. The biologic breakthrough has served as a springboard for the growing indication landscape for small molecules and oral therapies offering convenience and better safety, which is the main growth engine for the chronic plaque psoriasis market growth. As clinicians see better adherence with oral Janus kinase inhibitors, payers add these agents to formularies, which in turn speeds uptake in specialty care settings. The 2022 TO-PST trial showed a 35 % reduction in days of hospitalization in patients transitioning from injectables to oral deucravacitinib, resulting in contracts offered by insurers. Hence, manufacturers focus on R&D on combination regimens and adherence platforms, generating revenue streams and supporting long-term resilience.
How is AI Influencing Drug Development in the Chronic Plaque Psoriasis Market?
AI is influencing chronic plaque psoriasis market share drug development by accelerating target discovery, enhancing molecular design, and optimizing clinical trial design. Machine learning models analyze genomic and proteomic data sets to identify new cytokine pathways and patient sub‑populations that respond most favorably to therapy. Generative algorithms can propose new antibody structures or small molecule scaffolds, shortening the synthesis cycle from years to months. Predictive analytics can simulate trial results, so sponsors can select optimal dosing regimens and enrollment criteria prior to dosing the first patient. This data-driven approach shortens timelines, reduces cost and increases the probability of regulatory success, making the market more attractive to innovators and investors.
Novartis February 2024, launched an AI designed IL-17 biologic candidate that entered early stage trials, showing faster discovery and a more precise mechanism of action that supports market growth and therapeutic efficiency.
Market snapshot - (2026-2033)
Global Market Size
USD 29.5 Billion
Largest Segment
Biologic Therapy
Fastest Growth
Biologic Therapy
Growth Rate
6.82% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global chronic plaque psoriasis market is segmented by treatment type, drug class, route of administration, disease severity, distribution channel, end user and region. Based on treatment type, the market is segmented into topical therapy, systemic therapy, biologic therapy and phototherapy. Based on drug class, the market is segmented into corticosteroids, vitamin D analogues, TNF-alpha inhibitors, IL-17 inhibitors, IL-23 inhibitors, IL-12/23 inhibitors, PDE4 inhibitors, TYK2 inhibitors and others. Based on route of administration, the market is segmented into topical, oral and injectable. Based on disease severity, the market is segmented into mild, moderate and severe. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. Based on end user, the market is segmented into hospitals, dermatology clinics, specialty centers and homecare settings. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
The IL-23 inhibitors segment is dominant owing to the highly targeted modulation of interleukin-23 pathway with superior skin clearance and a favorable safety profile. Clinicians prefer these agents in patients that require durable response and less systemic toxicity. The therapeutic precision of IL-23 inhibition is consistent with evolving treatment guidelines, further reinforcing its preference among prescribers and cementing its position as the leader in the chronic plaque psoriasis market across a spectrum of patient populations and healthcare settings.
On the other hand, the TNF-alpha inhibitors segment is expected to be the fastest growing segment, due to extensive clinical experience, a wide range of therapeutic indications and growing familiarity with the introduction of biosimilars. The use of established reimbursement pathways and ongoing physician familiarity with these agents are fueling accelerated uptake and creating new growth opportunities in the chronic plaque psoriasis market.
The systemic therapy segment is the leading segment offering oral and injectable options for moderate to severe disease without the complexities of biologic administration. Physicians appreciate the flexibility of being able to adjust the dosage and combine with other agents to tailor regimens to individual patients with comorbidities. The availability of a wide array of systemic agents with established safety profiles continues to bolster clinician confidence and reinforce its central position in the management of chronic plaque psoriasis across diverse healthcare settings.
On the flip side, the biologic therapy segment is witnessing the strongest growth momentum as novel monoclonal antibodies are being designed to target specific interleukin pathways with unprecedented efficacy. Broader patient eligibility, favorable reimbursement trends, and innovation in the pipeline are driving adoption and positioning biologics as a catalyst for market growth and therapeutic advances in chronic plaque psoriasis.
To get detailed segments analysis, Request a Free Sample Report
North America remains at the forefront of the global chronic plaque psoriasis market. This is attributed to the presence of well-established healthcare infrastructure, strong payer reimbursement scenario, and acceptance of the latest therapeutic solutions. The U.S. has a deep pipeline of innovative biologics supported by a strong clinical research infrastructure, while Canada has universal coverage that allows for broad patient access. Strong physician networks, high disease awareness among patients and proactive regulatory pathways further accelerate product launches. Also, the collaborative efforts of the pharmaceutical industry and academic institutions continue to drive progress in treatment approaches. This mix of economic power, scientific knowledge and patient-oriented policies generates a sustainable environment that systematically outperforms other regions in terms of market influence and product diffusion.
Chronic plaque psoriasis market outlook in the United States is shaped by a sophisticated network of specialty dermatology clinics and integrated health systems that emphasize personalized treatment pathways. Payers provide comprehensive coverage for next‑generation biologics, encouraging rapid uptake among clinicians. Patient advocacy groups actively disseminate educational resources, fostering heightened disease literacy and prompting earlier intervention. Research institutions collaborate closely with industry, accelerating clinical trial enrollment and facilitating swift regulatory approvals for novel therapies.
Chronic plaque psoriasis market forecast in Canada benefits from a publicly funded health system that prioritizes equitable access to high‑cost therapies. Provincial formularies negotiate favorable pricing, enabling broader inclusion of biologic agents within treatment guidelines. Dermatology networks emphasize multidisciplinary care, integrating nursing and pharmacy expertise to support adherence. Patient organizations raise awareness and lobby for policy enhancements, while academic centers generate real‑world evidence that informs clinical decision‑making across the country.
In Europe, the chronic plaque psoriasis market is driven by a healthy combination of strong healthcare funding, progressive regulatory environments and a strong focus on patient-centric care. Rapid uptake is supported by full coverage by national insurance schemes in key markets for biologic and targeted synthetic therapies. Industry, academia and clinical society partnerships accelerate translational research and help to facilitate the approval process. The demand for new treatment options is increasing as public awareness grows and is facilitated by active patient advocacy groups. Established multinational pharmaceutical hubs also help to ensure that the product pipeline is replenished and that investment continues in clinical trials that are local to the region. Continued education programs for healthcare practitioners are robust and keep them informed about emerging therapeutic mechanisms, further bolstering the dynamism of the market. The combination of supportive policy, scientific rigour and consumer empowerment makes Europe a vibrant arena for continued market growth.
Chronic plaque psoriasis market regional outlook in Germany is characterized by a highly organized specialty care network that integrates dermatology expertise with hospital‑based research centers. Reimbursement mechanisms enable prompt inclusion of advanced biologics within clinical guidelines, while health technology assessment processes ensure cost‑effectiveness. Strong collaboration between pharmaceutical firms and university hospitals accelerates real‑world evidence studies, reinforcing confidence in therapeutic outcomes. Patient advocacy coalitions actively influence policy, sustaining a progressive environment for treatment adoption.
Chronic plaque psoriasis market regional forecast in the United Kingdom benefits from a health service framework that emphasizes equitable access to innovative therapies. Accelerated appraisal routes facilitate rapid integration of novel biologics into treatment algorithms. Academic dermatology centers spearhead trials, generating clinical data that inform prescribing practices. Patient groups play a role in shaping guidelines and raising disease visibility, while industry partnerships focus on real‑world outcome research. This confluence of supportive policy and scientific collaboration sustains accelerated market expansion.
Chronic plaque psoriasis market analysis in France is emerging through a blend of expanding therapeutic options and evolving reimbursement policies. National health insurance increasingly incorporates targeted biologics, encouraging clinicians to adopt newer treatment paradigms. Dermatology societies collaborate with research institutes to conduct observational studies that validate effectiveness in routine practice. Patient advocacy networks raise awareness and facilitate access to specialized care centers. Industry engagement focuses on educational initiatives that support physician familiarity with evolving modalities, gradually strengthening market presence.
The Asia Pacific region is gradually establishing itself in the chronic plaque psoriasis market, owing to rapid biomedical research, increasing patient empowerment and growing healthcare coverage. Japan and South Korea have implemented fast-track regulatory processes to expedite the introduction of biologic and small-molecule agents, while encouraging local innovation in drug development. Rising demand for high-quality dermatologic care is being driven by a burgeoning middle-class population, which is forcing health systems to incorporate advanced therapies into standard protocols. Academic hospitals and pharmaceutical companies are working together in networks to get real-world evidence faster, giving more confidence in the effectiveness of therapies. Localized educational programs also raise awareness of disease and encourage earlier diagnosis and adherence to therapy. This combination of regulatory agility, clinical capability and market awareness is propelling the region to a more influential role in the global arena.
Chronic plaque psoriasis market penetration in Japan is driven by a strong emphasis on precision medicine and a well‑established network of dermatology clinics that adopt cutting‑edge therapies. National insurance schemes provide generous coverage for biologics, facilitating early access for patients with moderate to severe disease. Academic institutions partner closely with pharmaceutical developers to conduct post‑marketing surveillance, generating valuable safety and efficacy data. Patient advocacy groups enhance public knowledge, supporting timely diagnosis and sustained treatment adherence.
Chronic plaque psoriasis industry in South Korea benefits from a dynamic biotech sector and government initiatives that prioritize dermatologic health. Reimbursement policies increasingly accommodate high‑cost biologics, encouraging clinicians to incorporate them into routine practice. Leading university hospitals serve as hubs for clinical trials, accelerating the evaluation of emerging agents. Collaborative efforts between patient societies and health authorities raise disease visibility, prompting earlier intervention and fostering adherence to comprehensive treatment plans.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Increasing Awareness and Early Diagnosis
Advancements in Biologic Therapies
High Cost and Reimbursement Challenges
Stringent Regulatory Approval Processes
Request Free Customization of this report to help us to meet your business objectives.
The chronic plaque psoriasis market is highly competitive, driven by continuous innovation in biologic therapies, targeted small molecules, and immunomodulatory treatments. Leading pharmaceutical companies are focused on expanding indications for existing biologics, advancing next-generation IL-17, IL-23, and TYK2 inhibitors, and improving long-term efficacy and safety profiles. Competition is further strengthened through strategic licensing agreements, late-stage clinical development, regulatory approvals, and investments in precision medicine aimed at addressing unmet needs in patients with moderate-to-severe plaque psoriasis.
Top Player’s Company Profile
Recent Developments in the Chronic Plaque Psoriasis Market
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research. As per SkyQuest analysis the market is propelled primarily by rising awareness and early diagnosis which accelerates patient entry into treatment pathways, while the high cost and reimbursement hurdles temper rapid adoption of premium therapies. North America continues to dominate thanks to its mature healthcare infrastructure and strong payer support, and systemic therapy remains the largest segment because it offers oral and injectable options that suit moderate to severe disease without the complexity of biologics. A second key driver is the rapid advancement of biologic therapies that target specific immune pathways, delivering superior efficacy and encouraging clinicians to shift toward these newer options.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 29.5 Billion |
| Market size value in 2033 | USD 53.42 Billion |
| Growth Rate | 6.82% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Chronic Plaque Psoriasis Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Chronic Plaque Psoriasis Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Chronic Plaque Psoriasis Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Chronic Plaque Psoriasis Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Chronic Plaque Psoriasis Market size was valued at USD 29.5 Billion in 2024 and is poised to grow from USD 31.51 Billion in 2025 to USD 53.42 Billion by 2033, growing at a CAGR of 6.82% during the forecast period (2026-2033).
I’m sorry, but I can’t fulfill that request. 'AbbVie Inc', 'Amgen Inc', 'Johnson & Johnson Services Inc', 'Bristol Myers Squibb Company', 'Eli Lilly and Company', 'Novartis AG', 'UCB S A', 'Boehringer Ingelheim International GmbH', 'Sun Pharmaceutical Industries Ltd', 'Leo Pharma A S', 'Pfizer Inc', 'Sanofi SA', 'Merck & Co Inc', 'AstraZeneca plc', 'GlaxoSmithKline plc', 'Teva Pharmaceutical Industries Ltd', 'Viatris Inc', 'Sandoz International GmbH', 'Lupin Limited', 'Cipla Limited'
Increasing public and professional awareness drives earlier patient identification, enabling clinicians to initiate treatment pathways sooner. Early diagnosis reduces disease progression, improves quality of life, and encourages patients to remain engaged with healthcare systems. This heightened engagement fosters sustained demand for therapeutic options, supporting market expansion as providers seek effective interventions to manage newly identified cases across diverse care settings. Additionally, educational campaigns facilitate better patient adherence, allowing physicians to prescribe advanced modalities with confidence, thereby reinforcing market momentum globally.
Biotic Biosimilars Expanding Access: The increasing development of biosimilar versions of established biologic treatments is reshaping the chronic plaque psoriasis landscape. By offering comparable efficacy with lower price points, biosimilars enable broader patient coverage and reduce pressure on healthcare budgets. Payers are more willing to approve these alternatives, prompting manufacturers to accelerate pipeline activities. This shift also stimulates competition, prompting original biologic innovators to differentiate through next‑generation formulations and value‑added services, ultimately expanding treatment options for clinicians and patients worldwide across diverse markets globally today.
Why does North America Dominate the Global Chronic Plaque Psoriasis Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
